One in four Americans can’t afford their prescription drugs.
No big surprise.
Price are higher than any other wealthy nation.
Here are some stunning examples: Johnson & Johnson’s arthritis drug Ustekinumab (Stelara) costs $79,000 in the U.S.
But it costs $20,000 in Canada and $12,000 in France.
For some people, accessing the pharmacy remains one of the biggest barriers to retrieving prescriptions.
A lack of social support, time constraints and limited access to convenient transportation are commonly cited as reasons users cannot get their medication, according to the Centers for Disease Control and Prevention.
But it’s not just patients who have difficulty getting to the pharmacy who benefit from mail-order pharmacies: These programs offer flexibility, time and cost-savings to all enrolled.
Today, things are constantly changing.
Especially when it comes to epilepsy medications and resources.
Some companies have expanded their programs or even offer new ones.
Others have cut their funds, and sadly others have ceased to exist.
Here’s a new and comprehensive list…